A Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo
Status:
RECRUITING
Trial end date:
2027-06-05
Target enrollment:
Participant gender:
Summary
The primary objective of the trial is to evaluate the safety of TEV-53408 administered subcutaneously for the treatment of adults with vitiligo.
A secondary objective is to further evaluate the safety of TEV-53408.
The planned study period per participant is 84 weeks including a screening period (up to 4 weeks), a 24-week open-label treatment period, a 16-week washout period, and a 40-week follow-up period.